(Q57876885)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Dampening the effect of drug resistance in HIV: a leap forward (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1

Jens D Lundgren

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

9 October 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

91-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

Development of antiretroviral drug resistance

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Risk of triple-class virological failure in children with HIV: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970278-X

7 January 2021

10.1016/S1473-3099(11)70278-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21988894%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference